Amgen's Repatha Contract With Harvard Pilgrim Includes A Full Refund
Harvard Pilgrim Chief Medical Officer Michael Sherman said the full warranty behind the agreement is the right kind of deal to balance access and cost.
You may also be interested in...
Agreement between Amgen/Novartis and Eli Lilly with Express Scripts on new migraine drugs could spur more demand by payers for simple, value-based outcomes deals.
The latest drug development news and highlights from our US FDA Performance Tracker.
Using a higher event rate typical of real-world, high-risk CV patients, Amgen asserts Repatha is cost effective at $9,669, the going discounted rate in the market. But criticism over the PCSK9 inhibitors' cost-effectiveness continues.